Based in Nairobi, Kenya, Dr. Allan Pamba joins the management team of Roche Diagnostics EMEA-LATAM, which is active in 155 countries and supports the corresponding Roche businesses. In countries where there is no Roche subsidiary, the EMEA-LATAM organization works with agents and suppliers to make the full range of diagnostic systems and services available to local customers.
In his new position, Dr. Allan Pamba will coordinate all Roche investments in Africa, working with existing African management centers and engaging with various internal and external stakeholders.
Roche is a Swiss pharmaceutical company with headquarters in Basel, Switzerland. Roche is one of the world’s leading research-based pharmaceutical and diagnostics companies. Roche is also the world’s largest biotech company with differentiated medicines in the fields of oncology, immunology, infectious diseases, ophthalmology and central nervous system diseases. Roche is also the world leader in in-vitro diagnostics, tissue-based cancer diagnostics and a pioneer in diabetes management.
The Roche Group operates in more than 100 countries and in 2019 employed approximately 98,000 people worldwide. In 2019, Roche also invested 11.7 billion Swiss francs in research and development and had sales of 61.5 billion Swiss francs. Genentech in the United States is a full member of the Roche Group. Roche is the majority shareholder of Chugai Pharmaceutical in Japan.
In Africa, Roche is active in the following countries, among others: Algeria, Botswana, Cameroon, Central African Republic, Egypt, Ethiopia, Ghana, Kenya, Mauritius, Morocco, Namibia, Nigeria, Senegal, Sudan, Tanzania and Uganda.
Leader in the medical sector
Dr. Allan Pamba holds a Master’s degree in Public Health in Developing Countries from the London School of Hygiene & Tropical Medicine and a Bachelor’s degree in Surgery from Moi University, a Kenyan public university located in Eldoret, Western Kenya. He brings to this new position exceptional knowledge and expertise in the multinational pharmaceutical industry as well as in the hospital sector.
Dr. Allan Pamba, it is explained, has used his practical leadership and change management skills to successfully restructure the corporate governance and operational strategy of Nairobi Hospital, lead GSK’s divestment in East Africa and 40 African countries, and manage crisis communications.
GSK Vice President
Dr. Allan Pamba began his career at GlaxoSmithKline (GSK) as a clinical leader and went on to hold several high-profile positions, including Chief Executive Officer of Nairobi Hospital, a position he held for only six months. He was GSK’s Vice President for Pharmaceuticals, East Africa and Government Affairs, Africa. He was responsible for GSK’s commercial operations in nine East African countries, responsible for the sustainable delivery of medicines and vaccines through innovative business models. He was also responsible for leading GSK’s external engagement in Africa and developing innovative partnerships to improve access to medicines and vaccines in 50 countries, including the 48 UN Least Developed Countries.
Dr. Allan Pamba joined GSK in 2005 and was initially involved in the strategic and tactical direction of research and development (R&D) programs on diseases in developing countries, particularly HIV and malaria. In addition, Dr. Allan Pamba has also led the medical governance of more than 30 large collaborative HIV trials in Africa and Asia and led a Phase III clinical development program with two large trials in Africa to develop a new antimalarial drug.
Established one of the first comprehensive HIV clinics
Dr. Allan Pamba has worked in clinical care in Kenya for government departments, mission hospitals and research hospitals. He conducted clinical trials on the management of severe malaria in children at the WellcomeTrust Research Unit in Kilifi, Kenya. Dr. Pamba established one of the first comprehensive HIV care clinics in a public facility in Kenya, supported by PEPFAR funding. He is particularly interested in equitable access to health care and overall development in less developed countries.
